Q3 2025 Earnings Call Transcript November 6, 2025 Invivyd, Inc. misses on earnings expectations. Reported EPS is $-0.06153 EPS, expectations were $-0.05. Operator: Good morning, everyone, and welcome ...

A Los Angeles judge has dismissed a wrongful death lawsuit filed by the family of a late longtime KISS guitar tech.

The discovery could serve as a starting point for antiviral strategies. A research team at Ruhr University Bochum, Germany, ...

India's Coronavirus Vaccine Market offers growth through government-led initiatives, robust manufacturing, and R&D in vaccine ...

There are few more divisive issues in medicine today than the topic of vaccines. Until COVID, most Americans were glad to have their children vaccinated against measles, mumps, rubella, polio, HepB, ...

Invivyd ( ($IVVD) ) has released its Q3 earnings. Here is a breakdown of the information Invivyd presented to its investors. Invivyd, Inc. is a ...

Often confused for a common cold, respiratory syncytial virus (RSV) can in fact be serious and should be studied more closely ...

Adolescents who were vaccinated against COVID-19 were less likely to develop long COVID after their first SARS-CoV-2 ...

Research led by the University of Washington reports on an AI-guided method that designs epitope-specific antibodies and ...

It's time for us to reconnect with the radical, system-changing spirit that was once at the heart of our field.

PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth ...